Early detection and screening of pancreatic cancer

Journal of the Pancreas

Volumn 12, Issue 2, 2011, Pages 83-85

  Gonda, Tamas A ^a   Saif, Muhammad Wasif ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Early detection of cancer; Metabolomics; Methylation; Pancreatic neoplasms

Indexed keywords

DNA; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DNA METHYLATION; EARLY DIAGNOSIS; ECHOGRAPHY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PALPATION; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE;

CPG ISLANDS; DNA METHYLATION; EARLY DIAGNOSIS; HUMANS; MASS SCREENING; METABOLOMICS; PANCREATIC NEOPLASMS;

EID: 79952797650     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol. Dec 2009;6(12):699-708.
2. Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an update. Dig Dis. 2010;28(4-5):645-656.
3. Strimpakos AS, Syrigos KN, Saif MW. The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver. Dec 2010;4(4):433-449.
4. Larghi A, Verna EC, Lecca PG, Costamagna G. Screening for pancreatic cancer in high-risk individuals: a call for endoscopic ultrasound. Clin Cancer Res. Mar 15 2009;15(6):1907-1914.
5. T. Nagasaka AG, N. Taniguchi, Y. Mori, K. Sigeyasu, E. Yamada, T. Oka, D. Sun, T. Fujiwara. Power of fecal DNA methylation analysis: Does it lead to development of a noninvasive screening tool for pancreatic cancer?. J Clin Oncol. 2011;29(Suppl 4):187.
6. Ahlquist DA. Molecular stool screening for colorectal cancer. Using DNA markers may be beneficial, but large scale evaluation is needed. BMJ. Jul 29 2000;321(7256):254-255.
7. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. Dec 23 2004;351(26):2704-2714.
8. Ahlquist DA. Next-generation stool DNA testing: expanding the scope. Gastroenterology. Jun 2009;136(7):2068-2073.
9. Chen WD, Han ZJ, Skoletsky J, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. Aug 3 2005;97(15):1124-1132.
10. Itzkowitz SH, Jandorf L, Brand R, et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. Jan 2007;5(1):111-117.
11. Itzkowitz S, Brand R, Jandorf L, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol. Nov 2008;103(11):2862-2870.
12. Itzkowitz SH. Incremental advances in excremental cancer detection tests. J Nail Cancer Inst. Sep 16 2009;101(18):1225-1227.
13. Nagasaka T, Tanaka N, Cullings HM, et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst. Sep 16 2009;101(18):1244-1258.
14. K. Owusu-Sarfo VA, N. Gowda, N. Shanaiah, B. Xi, E. G. Chiorean, D. Raftery. 1H NMR-based metabolic profiling of serum for the detection of pancreatic cancer. J Clin Oncol. 2011;29(Suppl 4):193.
15. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res. Jan 15 2009;15(2):431-440.
16. Bathe OF, Shaykhutdinov R, Kopciuk K, et al. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomarkers Prev. Jan 2011;20(1):140-147.
17. Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science. Apr 3 1992;256(5053):102-105.
18. Traverso G, Shuber A, Levin B, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med. Jan 31 2002;346(5):311-320.
19. Glockner SC, Dhir M, Yi JM, et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. Jun 1 2009;69(11):4691-4699.
20. Melotte V, Lentjes MH, van den Bosch SM, et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst. Jul 1 2009;101(13):916-927.